At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 13 enrolled
Drug / intervention
EXPARELdrug
Likely dose
EXPAREL 266 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Evaluation of the Safety and Efficacy of EXPAREL® When Infiltrated Into the Transversus Abdominis Plane (TAP) for Prolonged Postoperative Analgesia in Subjects Undergoing Unilateral Abdominal Hernia Repair
In Brief
A Phase 4 clinical trial evaluating EXPAREL for Hernia. Completed, enrolled 13 participants across 1 site.
Detailed Summary
Phase 4 study evaluating the effectiveness of EXPAREL when infiltrated into the the Transversus Abdominis Plane (TAP).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHernia
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartApr 2012
Primary CompletionDec 2012
First PostedFeb 2013
TodayJul 2026
First PostedFeb 28, 2013
Enrollment StartApr 1, 2012
Primary CompletionDec 1, 2012
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 13.3 years ago
Interventions
EXPARELdrug
single dose 266 mg of undiluted EXPAREL